$KROS

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. kros-20260717 0001664710 FALSE 0001664710 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Keros Therapeutics (Nasdaq: KROS) said Anne Prener, M.D., Ph.D., will join its Board of Directors effective July 1, 2026. The company cited her clinical development and executive leadership experience. Prener is a senior innovation advisor at the University of Copenhagen and a non-executive director of XSpray Pharma, and previously led Imbria Pharmaceuticals.

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. kros-20260623 0001664710 FALSE 0001664710 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Seth Alpna sold 2,625 shares of Keros Therapeutics, Inc. (KROS) at $10.72 on 2026-06-04 under a Rule 10b5-1 trading plan.

Keros Therapeutics director Jean Jacques Bienaime recently purchased 1,000 shares of the company's common stock for $11,700. This transaction was executed under a pre-arranged trading plan, and comes as the stock is down 43% year-to-date, though InvestingPro analysis suggests it may be undervalued. Keros Therapeutics also recently appointed Charles Newton to its Board of Directors to strengthen its leadership with financial expertise.

Keros Therapeutics (KROS) has appointed Charles Newton, former CFO of Lyell Immunopharma and a veteran healthcare investment banker, as a Class III director, effective March 9, 2026. Newton will also join the Compensation and Audit Committees, bringing extensive financial and capital markets expertise to support Keros's clinical pipeline. This appointment coincides with long-serving director Carl Gordon stepping down from the board.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its participation in three upcoming healthcare conferences in late February and early March 2026. President and CEO Jasbir S. Seehra, Ph.D., will present at these events, which include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. The company focuses on developing therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.

Keros Therapeutics (KROS) and argenex SE (ARGX) are evaluated as potential value stock opportunities in the Medical - Biomedical and Genetics sector. KROS, with a Zacks Rank of #1 (Strong Buy) and a Value grade of A, appears to be the superior option due to stronger earnings estimate revisions and more attractive valuation metrics like a forward P/E of 9.16 and a PEG ratio of 0.25, compared to ARGX's Zacks Rank of #3 (Hold) and Value grade of C.

KROS vs. NVZMY: Which Stock Is the Better Value Option?

The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.